| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | UTX; KABUK2; bA386N14.2 |
| Entrez GeneID | 7403 |
| clone | 5C2A9 |
| WB Predicted band size | 154kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human KDM6A (AA: 1252-1401) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于KDM6A抗体的3篇参考文献示例(内容为虚构，仅供格式参考)：
1. **文献名称**：*"Development and validation of a highly specific monoclonal antibody for KDM6A in human cancers"*
**作者**：Smith J, et al.
**摘要**：本研究开发了一种针对KDM6A蛋白C末端表位的单克隆抗体，验证了其在免疫组化(IHC)和Western blot中的特异性，并应用于多种癌症样本分析，发现KDM6A表达缺失与肿瘤侵袭性相关。
2. **文献名称**：*"KDM6A modulates chromatin dynamics during stem cell differentiation: Insights from antibody-based ChIP-seq analysis"*
**作者**：Lee H, et al.
**摘要**：通过优化KDM6A抗体的染色质免疫沉淀(ChIP)条件，揭示了KDM6A在胚胎干细胞分化过程中通过去甲基化H3K27me3调控关键基因(如HOX家族)的机制。
3. **文献名称**：*"Structural and functional characterization of KDM6A using a novel nanobody library"*
**作者**：Garcia R, et al.
**摘要**：基于骆驼源纳米抗体文库筛选出高亲和力KDM6A抗体，结合冷冻电镜解析了KDM6A与染色质复合物的互作结构，为靶向药物设计提供了新思路。
4. **文献名称**：*"KDM6A autoantibodies as a biomarker in autoimmune disorders"*
**作者**：Wang Y, et al.
**摘要**：首次报道了系统性红斑狼疮(SLE)患者血清中存在的抗KDM6A自身抗体，并发现其与疾病活动度相关，提示KDM6A可能参与表观遗传异常导致的自身免疫反应。
(注：以上文献为模拟示例，实际引用需检索真实数据库如PubMed或Google Scholar。)
The KDM6A antibody is a crucial tool in studying the KDM6A protein, a histone demethylase encoded by the *KDM6A* gene (also known as UTX). KDM6A belongs to the KDM6 subfamily of lysine demethylases and specifically removes repressive trimethyl marks from histone H3 lysine 27 (H3K27me3), a key epigenetic modification regulating gene expression. This enzyme plays vital roles in development, differentiation, and cellular identity, including X-chromosome inactivation and embryonic stem cell differentiation. Dysregulation or mutations in KDM6A are linked to cancers (e.g., T-cell acute lymphoblastic leukemia, renal cell carcinoma) and developmental disorders like Kabuki syndrome.
Antibodies targeting KDM6A enable researchers to detect its expression, localization, and interaction partners in various experimental setups, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP-seq). They are also used to study KDM6A’s role in chromatin remodeling, its cooperation with complexes like COMPASS or SWI/SNF, and its tumor-suppressive functions. Specificity validation is critical, as some commercial antibodies may cross-react with homologous proteins (e.g., KDM6B/UTY) or exhibit batch variability. Proper controls, such as knockout cell lines or siRNA-mediated depletion, are recommended to confirm antibody reliability. These tools continue to advance our understanding of KDM6A’s contributions to epigenetics, disease mechanisms, and potential therapeutic targeting.
×
